In addition to the so-called basic therapy employed in the treatment of rheumatoid arthritis, a number of drugs are in general use. Many years of experience have shown the value of aspirin, aminopyrin (pyramidon), phenylbutazone (butazolidin), and gold. This evaluation is based primarily on estimates of their antirheumatic and analgesic effects, as well as on considerations of the risk of toxicity.
It is not proposed to discuss the possibility of a distinct differentiation between the analgesic and antirheumatic effects of these drugs on the one hand and the antirheumatic and antiphlogistic properties on the other. This subject has been fully treated by Winder (1959) .
A better understanding of the course of rheumatoid arthritis treated exclusively with basic therapy has established that, because of the variable and unpredictable course of the disease, any evaluation of antirheumatic drugs must satisfy a number of demands. Such an evaluation can be carried out most successfully, by methods which have been worked out largely by British investigators, in so-called "double-blind" trials, by which neither the patient nor the investigator knows which drug is being administered.
A double-blind test with salicylamide and a placebo has been reported by Batterman and Grossman (1955) , but no similar study of the value of aminopyrin has come to the authors' attention. Five blind investigations of phenylbutazone have been reported (Steinbrocker, Berkowitz, Carp, Ehrlich, and Elkind, 1951; Ansell, Fearnley, Bywaters, and Meanock, 1953; Fjellstrom, Goldberg, Lindgren, and Nilsson, 1957; Smyth and Clark, 1957; Vaughn, Howell, and Kiem, 1959) . The method used by Hajnal, Sharp, and Popert (1959) , who tested aspirin, prednisone, and phenylbutazone, is not comparable with the usual double-blind type of trial.
Our object was not only to assess the clinical value of aspirin, aminopyrin, and phenylbutazone in relation to a placebo, but at the same time to compare these drugs with each other as regards therapeutic activity and toxicity.
Method
Material.-191 patients from the Clinical Centres for Rheumatic Diseases N and S (Rotterdam) with "definite rheumatoid arthritis" (A.R.A. criteria: Ropes, 1959) received, in addition to the basic treatment, a 6-week course of drugs in the form of powders. The choice of the first powder to be administered was determined by a random list, as was the order in which the drugs and the placebo were taken by the patient.
Disease Activity.-This was measured before and after the course of treatment according to four criteria:
( The 191 patients were grouped according to the number of the first drug used. The clinical details as at the start of the experiment are shown in Table I .
Dosage.-The following dosages were used:
Phenylbutazone, three daily doses of 200 mg.; Aminopyrin, 500 mg., three times daily; Aspirin, 1 g., three times daily (at the start of our trial it was not sufficiently known that the dose should have been at least 6 g. to be compared with 600 mg. phenylbutazone); Sach. lact., 1 g., three times daily. The powders were all given the same bitter taste by the addition of a small amount of quinine.
2 weeks after the conclusion of one course of powders the next drug in the series was administered for a further 6 weeks. In this way it was possible to compare the effect of various drugs on various patients, and all also received the basic treatment throughout the investigation.
Toxicity.-When toxic symptoms appeared, an attempt was made to carry on with a smaller dosage, but the administration was discontinued if toxic signs persisted, and a few patients defaulted.
In connexion with the danger of intoxication, all patients were checked weekly during the consulting hour as to their subjective complaints. Weekly procedures included a leucocyte count, and the urine was checked for albumen, urobilin and sediment.
Results Table II shows the percentage of patients who completed courses of each drug. The chances of completing the course decreased in the sequence I-II-III-IV; in other words, Drug IV seems to have been more toxic than Drug I; the differences in frequency of completion, however, are not significant. The numbers of separate complaints are too small for the differences to be significant. There was no indication that the frequency of discontinuation depended on the drug with which the series was begun. Table IV gives the means of the results obtained by evaluating the courses of each drug separately. Table I shows that the four groups to which patients (Table  V) and that obtained by evaluating the courses of each drug separately (collective average, see Table  IV ).
Grip. -The sequence in both Tables is I, III,  II, IV. Pain.-There is agreement for I and III and disagreement for II 
The result of each comparison is given by an arrow; the points of the arrows indicate the best results. A double arrow is used when the difference is significant at the 5 per cent. level. I-III-II-IV  I-III-IV-II  l-II-IV-III  l-I-III-IV Sequence According to Collective Average: 1-111-11-1Vt 11*| SIgnlt-fvt aV-t the l5 It-lpt-entt-lvt TRIAL OF ANTIRHEUMATIC DRUGS Conclusion The placebo as well as the drugs had, as was to be expected, a favourable effect on the symptoms of rheumatoid arthritis. This must be ascribed to the happily ever-present tendency to spontaneous recovery from rheumatoid arthritis, and also to the effect of suggestion which is inherent in all placebos.
Aspirin, aminopyrin, and phenylbutazone, however, had an appreciably better effect than the placebo, and of these phenylbutazone gave the best results. The authors wish to confine their conclusions from this experiment to the statement that, in this trial (bearing in mind the inadequacy and limitations of the quantitative criteria), phenylbutazone proved to be a better analgesic drug in cases of rheumatoid arthritis, than aminopyrin or aspirin in the dosages used.
The number of discontinued courses indicates that the administration of a placebo may be followed by the signs and symptoms of toxicity and intolerance (Table III) . The clear-cut decrease in the number of leucocytes in patients taking the placebo must certainly have been due to a spontaneous fluctuation in the leucocyte count, but it led the authors, with exaggerated caution, to terminate the course.
The fact that toxicity increased in the sequence placebo, aspirin, aminopyrin, and phenylbutazone points to the conclusion that phenylbutazone is most likely to cause toxic reactions, although the differences were not large enough in these series to be significant.
Summary
In a "double-blind" trial of drugs in the treatment of rheumatoid arthritis, 191 patients with definite rheumatoid arthritis (American Rheumatism Association criteria) were given in four successive courses of 6 weeks: three daily doses of 1 g. aspirin, three daily doses of 0 5 g. aminopyrin, three daily doses of 200 mg. phenylbutazone, and three daily doses of a placebo.
All the powders looked the same and had the same taste. The order in which the drugs and the placebo were taken by the patient was determined by chance. Between each period of 6 weeks there was an interval of 2 weeks.
All the patients were examined at the beginning and end of each period by one of the authors and the improvement or deterioration was noted according to the following criteria:
(1) Hand grip (mm. Hg); (2) Tenderness on pressure (metacarpophalangeal joints); (3) Erythrocyte sedimentation rate (Westergren); (4) Subjective judgment of the therapeutic result.
The results of this trial suggest that, in the dosages used, phenylbutazone is the best analgesic drug in rheumatoid arthritis, followed by aminopyrin and aspirin in that order, and the authors desire to limit their conclusions to this statement. Toxic reactions were least with the placebo, and increased with aspirin, aminopyrin, and phenylbutazone in that order, but the differences are not large enough to be significant in this series of patients. 
